As AI accelerates antibody discovery, experimentally validating predicted antibody–antigen interactions is becoming increasingly important. By leveraging high-throughput 3D epitope mapping, enabled by cryo-EM and integrated computational analysis, it is now possible to provide the structural insights needed to confirm binding mechanisms, differentiate lead candidates, and support AI-assisted antibody discovery workflows.
Antibody discovery has traditionally depended on experimental screening methods such as animal immunization and display-library selection [1]. Recent advances in generative AI are beginning to change this process by enabling computational prediction of novel antibody candidates and likely binding properties [2]. Some AI-based antibody discovery platforms have reported approximately 60% reductions in discovery timelines and 50% reductions in cost compared to traditional methods, and pharma-AI partnerships are accelerating [1]. In a recent Nature Communications study, researchers used the Fold platform to computationally design antibodies against multiple therapeutically relevant antigens before experimentally validating high-affinity binding and intended epitope targeting [3].
The AI-in-antibody-discovery market reached roughly $410 million in 2024, with projections of approximately 25% annual growth through 2035 [4]. As computational approaches mature, experimentally confirming predicted antibody–antigen interactions is becoming increasingly important.
The central limitation of sequence-driven AI models is that binding behavior is ultimately structural, not purely sequential. Two antibodies with highly similar sequences can still engage the same target differently, with even subtle structural shifts altering affinity, specificity, downstream function or mode of action. Current in silico prediction methods still struggle to consistently capture these spatial relationships across diverse antigen targets [5].
The limitations of current training datasets—particularly the lack of experimentally verified negatives and robust structural context—can cause models to overfit sequence-level patterns that do not reliably predict functional binding [6].
While AI models can predict likely binders, they often lack direct insight into the true three-dimensional binding interface. 3D Epitope mapping provides that missing structural information by experimentally (i.e. empirically) revealing how and where an antibody engages its target [7]. High-resolution 3D epitope mapping can uncover mechanistic differences between antibodies that may otherwise appear similar in traditional screening assays.
Recent work on PAD4, an enzyme implicated in rheumatoid arthritis, illustrates this clearly. Cryo-EM epitope mapping showed that two antibodies with similar binding affinities produced opposite functional effects due to differences in how they stabilized the enzyme’s structure [8]. Affinity measurements alone could not have distinguished these candidates.
In practice, AI models first predict antibody candidates and their predicted epitopes. High-throughput 3D epitope mapping can then be applied to selected lead candidates experimentally and resolve the true antibody–antigen interface, including contact residues, binding orientation, conformational effects, and steric relationships and a much better understanding of the mode of action (MOA) of each candidate.
ATEM’s high-throughput 3D epitope mapping platform therefore combines highly streamlined cryo-EM workflows with integrated computational analysis to rapidly resolve antibody–antigen complexes at a fit-for-purpose resolution. This approach enables characterization of glycosylated, membrane-bound, and other difficult-to-crystallize complexes, delivering up to five structures in as few as three weeks.
This structural information then helps engineering teams to validate predicted epitopes, distinguish mechanistic differences between candidates, confirm target engagement, and prioritize the most promising therapeutic leads for downstream optimizations.
AI-based antibody discovery is only as strong as the experimental data used to validate it. As antibody discovery becomes faster and increasingly computational, high-throughput 3D epitope mapping will play a growing role in confirming binding mechanisms, differentiating lead candidates, and connecting computational prediction with experimentally resolved structural insight.
If your team is looking to integrate high-throughput 3D epitope mapping into antibody discovery or candidate validation workflows, ATEM’s cryo-EM-powered platform is designed to deliver rapid, high-resolution structural insight at scale.
You are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from HubSpot. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Hubspot Meetings. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information